Senhwa Biosciences, Inc. (TPEX:6492)
29.70
-0.15 (-0.50%)
Nov 13, 2026, 1:24 PM CST
Senhwa Biosciences Revenue
Senhwa Biosciences had revenue of 240.00K TWD in the quarter ending September 30, 2026, a decrease of -27.27%. This brings the company's total for the last twelve months to 960.00K, down -11.11% year-over-year. In the year 2025, Senhwa Biosciences had annual revenue of 1.07M with 7.00% growth. That makes Senhwa Biosciences the 46,883rd largest company in the world by revenue and 2,201st in Taiwan.
Revenue (ttm)
960.00K
Revenue Growth
-11.11%
P/S Ratio
2,765.38
Revenue / Employee
n/a
Employees
n/a
Market Cap
2.65B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.07M | 70.00K | 7.00% |
| Dec 31, 2024 | 1.00M | - | - |
| Dec 31, 2023 | 1.00M | - | - |
| Dec 31, 2022 | 1.00M | 450.00K | 81.82% |
| Dec 31, 2021 | 550.00K | -67.00K | -10.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Syngen Biotech | 2.05B |
| Chunghwa Chemical Synthesis & Biotech | 934.29M |
| Sagittarius Life Science | 467.69M |
| BioGend Therapeutics | 235.24M |
| Intech Biopharm | 54.34M |
| Formosa Pharmaceuticals | 51.67M |
| Shine-On BioMedical | 50.62M |
| GlycoNex Incorporation | 19.51M |
Senhwa Biosciences News
- 1 year ago - Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Benzinga